Decisions regarding pro re nata medications might be challenging due to the complex nature of the practice. The aim of this study was to expand our understanding of the experiences of older people living in sheltered housings with regard to shared decision-making concerning pro re nata medications. In this study, we conducted in-depth interviews with residents living in Norwegian sheltered housings. The analysis was inductive, based on a narrative positioning analysis. Twelve residents were interviewed, and three narratives representing participants' variation are presented. People take different positions in shared decision-making of pro re nata medication, and they position themselves variously at different levels and situations. Prevailing master narratives affect the residents' positions in shared decision-making. Contrasts in older adults' experiences indicate that shared decision-making is not straightforward and is highly reliant on the context. Seemingly, they wish to be involved and not involved at the same time, a contradiction that healthcare providers need to consider.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611287PMC
http://dx.doi.org/10.1177/23333936211056930DOI Listing

Publication Analysis

Top Keywords

pro nata
16
shared decision-making
16
living sheltered
8
narrative positioning
8
positioning analysis
8
nata medications
8
sheltered housings
8
positions shared
8
older adults
4
adults living
4

Similar Publications

Background: Pro re nata (PRN) medication is used "as needed" for symptoms such as agitation and insomnia, in addition to regular daily pharmacotherapy of mental disorders. However, there is no high-quality evidence on the effectiveness of psychotropic PRN medications and concerns have been raised about their potential to contribute to polypharmacy. This study introduced a psychotropic PRN prescription-monitoring programme for psychiatric inpatients with the aim of examining the change before and after the implementation of the programme.

View Article and Find Full Text PDF

Background/objectives: Neovascular age-related macular degeneration (nAMD) is a retinal disorder leading to irreversible central vision loss. The pro-re-nata (PRN) treatment for nAMD involves frequent intravitreal injections of anti-VEGF medications, placing a burden on patients and healthcare systems. Predicting injections needs at each monitoring session could optimize treatment outcomes and reduce unnecessary interventions.

View Article and Find Full Text PDF

Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.

Methods: This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the quality of referrals to community palliative care teams, focusing on patient criteria for at-home care and the challenges in transitioning from hospital care to specialized palliative support.
  • Researchers analyzed patient records from 2023, noting an average patient age of 80.7 years, with common diagnoses including cancer and organ failure, and found improvements in psychological and social support after starting palliative care.
  • The findings suggest that while many patients can be supported effectively at home, there are significant issues with recognizing referral criteria and delays in transitioning care from hospitals.
View Article and Find Full Text PDF

Purpose: The natural course of the visual acuity in eyes with myopic macular neovascularization (myopic MNV) is poor. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents have demonstrated safety and efficacy in the short-term for managing myopic MNV. The purpose of this study was to determine the 4-year outcomes of intravitreal aflibercept (IVA) injections.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!